Theron (Ted) Odlaug, PhD

Ted previously served two terms on the Board of Directors of the Dravet Syndrome Foundation. He is a Venture Partner at Signet Healthcare Advisors, and a board member of CoreRx Inc. He is also on the Advisory Board of Carstens Inc. Prior he was CEO of Waverley Pharma Inc., Executive Chairman of Impopharma Inc. and CEO of leon-nanodrugs GmbH, and a member of its Supervisory Board. He was the Executive Chairman of Cedarburg Pharmaceuticals until the company was sold to Albany Molecular Research Inc. in 2014. From 2011 Ted was the Executive Chairman and CEO of Planet Biopharmaceuticals until the company was sold to Ares Life Sciences in 2014. From 2008 until 2011, he was President and CEO of CyDex Pharmaceuticals, Inc. at which time the company was sold to Ligand Pharmaceuticals, Inc. Prior to CyDex, Dr. Odlaug served as Managing Partner of EIR Healthcare Advisors, LLC, which he still uses for his consulting business. Prior to that, he was Executive Vice President and a member of the senior management committee at Fujisawa Healthcare Inc. until its merger with Yamanouchi in 2005, which resulted in the formation of Astellas Pharma. Earlier in his career he had senior positions at Bayer and Baxter. Ted holds Bachelor's and Master's degrees from the University of Missouri at Kansas City and a PhD in Public Health from the University of Minnesota

Ted Odlaug DSF Board Member

My granddaughter has a rare disease. But clinical trials often exclude patients like her.

As the grandfather of a girl with a rare disease, I’ve learned that for families like ours, hope often comes not as a cure, but as a clinical trial: carefully designed but inevitably exclusive. My granddaughter Anna has Dravet syndrome, a catastrophic childhood epilepsy most often caused by mutations in the SCN1A gene. Like many […]

My granddaughter has a rare disease. But clinical trials often exclude patients like her. Read More »

Scroll to Top